IFLR1000

Urovant Sciences $100 million financing

22/2/2019
Financing
Select tab

$ 100 million

Completed

22/2/2019

Overview:

  • Biopharmaceutical company Urovant Sciences has acquired $100 million financing from Hercules Capital.
  • The financing will be used to fund the development of lead compound vibegron, business development opportunities and general corporate purposes.

Rajeeb Gurung - Researcher

Jurisdiction:

Switzerland

Deal type:

Financing

Practice area:

Banking

Industry sector:

Pharmaceuticals and life sciences

Firms:
Homburger

Party: Hercules Capital (Lender)

Latham & Watkins

Party: Hercules Capital (Lender)

O'Melveny & Myers

Party: Urovant Sciences (Borrower)

VISCHER

Party: Urovant Sciences (Borrower)

Lawyer: Adrian Dörig

Related deals